Subcutaneous Implantable Cardioverter Defibrillator
Subcutaneous implantable devices safe for patients with congenital heart disease
Subcutaneous implantable cardioverter defibrillators are effective in preventing arrhythmic death in people with congenital heart disease, with the devices successfully terminating all life-threatening ventricular arrhythmias, data show.
Subcutaneous ICD extraction feasible, not linked to complications
Extraction of a subcutaneous implantable cardioverter defibrillator was safe and feasible and produced no complications, according to registry data presented at Heart Rhythm 2023.
ATLAS
Assessing major perioperative, lead-related complications in subcutaneous vs. transvenous ICD.
Subcutaneous ICD reduces rate of major lead-related complications: ATLAS
Among patients who received implantable cardioverter defibrillator therapy, a subcutaneous vs. transvenous approach reduced major lead-related complications by 92% with no loss in device performance, according to data from the ATLAS trial.
2-year complication rate for subcutaneous ICDs nearly 10%
According to real-world data, for patients undergoing subcutaneous implantable cardioverter defibrillator implantation, the overall complication rate was 9.3% during the first 2 years after implantation.